There is a clearer consensus of molecular classifications in breast cancer (Perou et al., 2000; Sorlie et al., 2001; Coates et al., 2015) that could be due to the presence of confirmed biomarkers (for example, hormonal receptors, and HER2 expression). This evidence concerns the gene ERBB2 and breast cancer.